2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
Avatar

2020 ASCO Update on B-cell Lymphomas: Does Allogeneic anti-CD19 CAR-T Induce High Response Rates?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Jakub Svoboda
By 2020 ASCO Virtual Direct™ Highlights FEATURING Jakub Svoboda
17 views
August 6, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

20:59
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Hematologic Oncology
10:54
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on AML: Does ENA+AZA Combo Improve Remission and O…

Feat. R. Redner
02:50
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on CP-CML: Does Changing Ponatinib Dose Result in I…

Feat. R. Redner
11:15
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: How Safe Is AMG 330? Is the Addition of Pev…

Feat. R. Redner
07:22
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Multiple Myeloma: What Are the Response Rate…

Feat. R. Redner
07:38
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on B-cell Lymphomas: Does Allogeneic anti-CD19 CAR-…

Feat. J. Svoboda
07:24
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Aggressive B‐Cell Lymphomas: Does Venetoclax Boo…

Feat. J. Svoboda
10:24
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on CLL: Does Time‐limited Triplet Therapy (BOVen) I…

Feat. J. Svoboda
09:29
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Multiple Myeloma: Should We Consider Idecabtagen…

Feat. J. Svoboda
17:40
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on R/R Indolent Lymphoma: Is Anti-CD19 CAR-T Axi-ce…

Feat. J. Svoboda
06:05
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Classical Hodgkin Lymphoma: Does Pembrolizumab I…

Feat. J. Svoboda